GlaxoSmithKline Pharma's Q1FY17 declines 22% to Rs 38 crore
It’s operating profit (EBITDA – earnings before interest tax depreciation and tax) stood at Rs 90.35, recording drop of 18.69% yoy and 29.91% qoq. While the company’s OPM (operating profit margin) was at 12.80%, contracting by 424 bps yoy and 544 bps qoq.
GlaxoSmithKline Pharmaceuticals reported net profit of Rs 38.55 crore, registering decline of 22.41% yoy (year-on-year) and 31.62% qoq (quarter-on-quarter).
The total income of the company was around Rs 705.33 crore, which grew by 8.22% but remained was slightly down by 0.13% qoq.
It’s operating profit (EBITDA – earnings before interest tax depreciation and tax) stood at Rs 90.35, recording drop of 18.69% yoy and 29.91% qoq. While the company’s OPM (operating profit margin) was at 12.80%, contracting by 424 bps yoy and 544 bps qoq.
The company’s earnings per share (EPS) was around Rs. 8.5 per share.
The Q1FY17 has been presented in accordance with the companies Indian accounting standard rule (Ind-AS).
The share price of GlaxoSmithKline Pharmaceuticals closed at Rs 3347.50 down by 30.05 points or 0.89%.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
04:01 PM IST
GlaxoSmithKline Pharmaceuticals Q2 net profit rises 16% to Rs 252 crore
GlaxoSmithKline Pharma Q3 Results: Net profit dips 72% to Rs 46 crore 
Technical Check: This pharma stock poised for over 30% upside in next 6 months; here’s why